Transgenic Group Inc.
Stock Price Chart
2026/08/12 UpdatedPrice Trend
2026/08/12 UpdatedPrice & Trading Details
2026/08/12 UpdatedPRICE
TRADING
Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2016/02/03 | ¥13.24 | ¥-1.17 | -108.8% |
| 2015/08/05 | ¥-1.06 | ¥-5.28 | -399.1% |
| 2015/05/13 | ¥9.65 | ¥10.70 | +10.9% |
| 2015/02/04 | ¥-0.71 | ¥0.12 | +116.9% |
Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/09| Year | Dividend | Change |
|---|---|---|
| 2024 | ¥3 | -40.0% |
| 2023 | ¥5 | -16.7% |
| 2022 | ¥6 | +100.0% |
| 2021 | ¥3 | - |
Financial Performance
2026/08/09 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥11,430M | ¥13,083M | ¥13,005M | ¥13,174M |
| Gross Profit | ¥1,995M | ¥2,249M | ¥2,167M | ¥2,434M |
| Operating Income | -¥25M | ¥89M | -¥260M | ¥138M |
| Pretax Income | -¥303M | ¥91M | -¥639M | -¥162M |
| Net Income | -¥410M | ¥4M | -¥1,090M | -¥77M |
| EPS | -¥24.32 | ¥0.24 | -¥65.51 | - |
| Operating Margin | -0.22% | 0.68% | -2.00% | 1.05% |
| Balance Sheet | ||||
| Total Assets | ¥10,673M | ¥9,811M | ¥9,586M | ¥9,735M |
| Total Equity | ¥6,018M | ¥5,894M | ¥4,763M | ¥4,780M |
| Total Liabilities | ¥4,655M | ¥3,917M | ¥4,824M | ¥4,955M |
| Cash | ¥3,459M | ¥2,478M | ¥2,555M | ¥2,135M |
| Interest-bearing Debt | ¥2,417M | ¥2,222M | ¥2,575M | ¥2,089M |
| Equity Ratio | 56.39% | 60.08% | 49.68% | 49.10% |
| D/E Ratio | 0.40 | 0.38 | 0.54 | 0.44 |
| Cash Flow | ||||
| Operating CF | -¥1,430M | -¥392M | ¥94M | ¥26M |
| Investing CF | -¥216M | -¥281M | -¥288M | ¥51M |
| Financing CF | ¥485M | -¥343M | ¥265M | -¥518M |
| Free CF | -¥1,736M | -¥658M | -¥81M | -¥43M |
| Efficiency | ||||
| ROE | -6.81% | 0.07% | -22.88% | -1.62% |
| ROA | -3.84% | 0.04% | -11.37% | -0.79% |
Latest IR Information
-
Q1 Fiscal Year Ending March 2027 Financial Summary (Japan GAAP) [Consolidated]
For the first quarter of the fiscal year ending March 2027, consolidated net sales were 36,590 million yen, up 14.4% YoY; operating profit was 163.5 million yen; ordinary income was 156.383 million yen; net income attributable to owners of the...
Read more -
Notice Regarding Disposition of Treasury Stock as Restricted Stock for Directors and Employees
Read more
Latest News (5 items)
Company Information
About
Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment and Consulting Business segments. The company provides analysis of the function of individual genes in individuals, elucidation of the relationship between genes and pathology, production of disease model mice, gene expression analysis, and antibody production; clinical trials for pharmaceutical agents, such as bioequivalence studies; administrative services for clinical trials; clinical trials for foods for specified health uses; and hospital support. It also conducts non-clinical studies for pharmaceuticals, medical devices, chemical substances, and food development using small and large animals. In addition, the company offers services related to mergers and acquisitions, business revitalization, business succession, and investment business. The company was formerly known as Trans Genic Inc. and changed its name to Transgenic Group Inc. in October 2024. Transgenic Group Inc. was incorporated in 1998 and is headquartered in Fukuoka City, Japan.
